ArticleFrontiers in oncology2025
Temporal dynamics of cisplatin-induced endothelial senescence and its association with cognitive impairment: insights into the medial prefrontal cortex.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy-related cognitive impairment (CRCI) poses significant challenges for cancer survivors, with its underlying mechanisms remaining inadequately understood, particularly in the medial prefrontal cortex (mPFC). This study aimed to investigate the temporal dynamics of cisplatin-induced endothelial senescence, blood-brain barrier (BBB) integrity, neuroinflammation, and their relationship with persistent working memory impairment. Methods: Adult C57BL/6 mice were treated with cisplatin (2.3 mg/kg) and evaluated at multiple time points post-treatment. Senescence-associated β-galactosidase (SA-β-gal) staining, secretory phenotype (SASP) factors, and expression of p16/p21 proteins were assessed to determine endothelial senescence. BBB integrity was determined using dextran tracer and analysis of tight junction proteins (Claudin-5, ZO-1). Neuroinflammation was investigated via GFAP and Iba1 staining. Cognitive function expression was assessed through the Novel Object Recognition (NOR), Puzzle Box, and modified T-maze tests, focusing on working memory ability. Results: Cisplatin triggered endothelial senescence in the mPFC, peaking at 1 week, as evidenced by elevated percentage of SA-β-gal positive area, increased SASP factors and p16/p21 expression. BBB dysfunction and glial activation emerged later (peaking at 4 weeks), with significant dextran leakage, reduced Claudin-5/ZO-1 levels and increased GFAP and Iba1 staining respectively. Unlike the early vascular events, showing initial rise followed by slow decline, cisplatin-induced working memory impairment persists through 4-12 weeks, manifested as reduced NOR discrimination index, prolonged times in Puzzle Box, and impaired T-maze performance. Conclusion: This study delineates a temporal cascade wherein cisplatin induces early mPFC endothelial senescence with delayed BBB dysfunction and neuroinflammation, driving chronic working memory impairment, thus indicating endothelial senescence as early-stage potential target for mitigating CRCI, especially in mPFC-related working memory deficits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.